KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 2,394 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 2,394 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $10.02, for a total value of $23,987.88. Following the completion of the sale, the insider now directly owns 102,940 shares in the company, valued at approximately $1,031,458.80. The trade was a 2.27 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV traded up $0.42 during trading on Tuesday, reaching $10.77. The company had a trading volume of 1,053,649 shares, compared to its average volume of 340,351. The firm’s fifty day moving average is $8.94 and its 200 day moving average is $10.35. The firm has a market capitalization of $532.23 million, a PE ratio of -2.96 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.01. Equities analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors have recently made changes to their positions in KALV. Suvretta Capital Management LLC raised its holdings in shares of KalVista Pharmaceuticals by 16.6% in the 4th quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company’s stock worth $41,613,000 after purchasing an additional 701,007 shares in the last quarter. Tang Capital Management LLC raised its holdings in shares of KalVista Pharmaceuticals by 13.2% in the 4th quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company’s stock worth $41,451,000 after purchasing an additional 572,300 shares in the last quarter. Frazier Life Sciences Management L.P. raised its holdings in shares of KalVista Pharmaceuticals by 32.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company’s stock worth $41,400,000 after purchasing an additional 1,200,000 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of KalVista Pharmaceuticals by 19.3% in the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company’s stock worth $40,402,000 after purchasing an additional 770,000 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of KalVista Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock worth $19,102,000 after purchasing an additional 104,716 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. TD Cowen started coverage on shares of KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $30.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Bank of America started coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).